Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)

NCT: NCT06222788 · RECRUITING

NCT IDNCT06222788
StatusRECRUITING
Start Date2025-04-07
Completion2028-12
SponsorCentre hospitalier de l'Université de Montréal (CHUM) (OTHER)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are: * To determine the safe and tolerable dose of NTP in patients with breast cancer; * To assess the safety and tolerability of NTP; * To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.

Frequently Asked Questions

What is Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)?

Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT) is a clinical trial registered under NCT06222788. Current status: RECRUITING.

What is the status of NCT06222788?

The current status of NCT06222788 (Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)) is: RECRUITING.

When did Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT) start?

Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT) started on 2025-04-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.